Shionogi & Co., Ltd. Unsponsored ADR (SGIOY) Stock Price, News & Analysis

Company Overview

Shionogi & Co., Ltd. is a Japan-based research-driven pharmaceutical company headquartered in Osaka. Founded in 1878, the company discovers, develops, manufactures and markets prescription medicines, with a focus on infectious diseases, central nervous system disorders and other areas of unmet medical need.

Shionogi’s portfolio includes Xofluza (baloxavir marboxil), an antiviral treatment for influenza, and F. (fostemsavir), an HIV treatment marketed in certain regions. The company also develops medicines for conditions including pain, psychiatric disorders and other diseases, while pursuing research in areas such as antimicrobial resistance and novel anti-infective therapies.

Shionogi primarily serves the Japanese market and has expanded its international presence through subsidiaries, licensing arrangements and commercial partnerships in North America, Europe and other regions. The company conducts research and development, manufacturing and commercialization activities through its own operations and collaborations with other pharmaceutical organizations.

Key Stats

• Today's Range: $9.05 to $9.14
• 50-Day Range: $8.61 to $9.56
• 52-Week Range: $7.65 to $12.00
• Volume: 66,595 shs
• Average Volume: 196,190 shs
• Market Capitalization: $15.42 billion
• P/E Ratio: 9.06
• Dividend Yield: 1.55%
• Price Target: N/A
• Consensus Rating: Buy

Shionogi & Co., Ltd. Unsponsored ADR Stock Analysis - MarketRank™

Shionogi & Co., Ltd. Unsponsored ADR scored higher than 39% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 1.9 / 5
• Analyst Rating: Buy

Consensus Rating

Shionogi & Co., Ltd. Unsponsored ADR has received a consensus rating of Buy. The company's average rating score is 3.33, and is based on 2 strong buy ratings, no buy ratings, 1 hold rating, and no sell ratings.

Amount of Analyst Coverage

Shionogi & Co., Ltd. Unsponsored ADR has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 1.3 / 5
• Proj. Earnings Growth: -3.66%

Earnings Growth

Earnings for Shionogi & Co., Ltd. Unsponsored ADR are expected to decrease by -3.66% in the coming year, from $0.82 to $0.79 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Shionogi & Co., Ltd. Unsponsored ADR is 9.06, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 44.47.

Price to Earnings Ratio vs. Sector

The P/E ratio of Shionogi & Co., Ltd. Unsponsored ADR is 9.06, which means that it is trading at a less expensive P/E ratio than the Healthcare sector average P/E ratio of about 273.68.

Price to Earnings Growth Ratio

Shionogi & Co., Ltd. Unsponsored ADR has a PEG Ratio of 3.26. PEG Ratios above 1 indicate that a company could be overvalued.

Price to Book Value per Share Ratio

Shionogi & Co., Ltd. Unsponsored ADR has a P/B Ratio of 1.39. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

0.08% of the float of Shionogi & Co., Ltd. Unsponsored ADR has been sold short.

Short Interest Ratio / Days to Cover

Shionogi & Co., Ltd. Unsponsored ADR has a short interest ratio ("days to cover") of 2.21, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Shionogi & Co., Ltd. Unsponsored ADR has recently increased by 3,691.12%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 2.5 / 5
• Dividend Strength: Moderate

Dividend Yield

Shionogi & Co., Ltd. Unsponsored ADR pays a meaningful dividend of 1.54%, higher than the bottom 25% of all stocks that pay dividends.

Dividend Growth

Shionogi & Co., Ltd. Unsponsored ADR does not have a long track record of dividend growth.

Dividend Coverage

The dividend payout ratio of Shionogi & Co., Ltd. Unsponsored ADR is 14.00%. This payout ratio is at a healthy, sustainable level, below 75%.

Dividend Sustainability

Based on earnings estimates, Shionogi & Co., Ltd. Unsponsored ADR will have a dividend payout ratio of 17.72% next year. This indicates that Shionogi & Co., Ltd. Unsponsored ADR will be able to sustain or increase its dividend.

News and Social Media

• Score: 2.4 / 5
• News Sentiment: 0.76

News Sentiment

Shionogi & Co., Ltd. Unsponsored ADR has a news sentiment score of 0.76. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 4 news articles for Shionogi & Co., Ltd. Unsponsored ADR this week, compared to 0 articles on an average week.

Company Ownership

• Score: 0.0 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Shionogi & Co., Ltd. Unsponsored ADR insiders have not sold or bought any company stock.

Percentage Held by Institutions

1.92% of the stock of Shionogi & Co., Ltd. Unsponsored ADR is held by institutions.

Company Calendar

• Last Earnings: 8/03/2026
• Today: 9/30/2026
• Next Earnings (Estimated): 10/26/2026
• Fiscal Year End: 3/31/2027

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Healthcare
• Industry: Pharmaceuticals
• Sub-Industry: Pharmaceuticals
• Current Symbol: OTCMKTS:SGIOY
• CIK: 1281721
• Web: shionogi.com
• Phone: (166) 202-2161
• Fax: N/A
• Employees: 6,223
• Year Founded: 1878

Profitability

• EPS (Trailing Twelve Months): $1.00
• Trailing P/E Ratio: 9.06
• Forward P/E Ratio: 11.05
• P/E Growth: 3.26
• Net Income: $1.35 billion
• Net Margins: 46.67%
• Pretax Margin: 47.81%
• Return on Equity: 16.13%
• Return on Assets: 12.09%

Debt

• Debt-to-Equity Ratio: 0.01
• Current Ratio: 1.14
• Quick Ratio: 1.00

Sales & Book Value

• Annual Sales: $3.32 billion
• Price / Sales: 4.65
• Cash Flow: $0.90 per share
• Price / Cash Flow: 10.03
• Book Value: $6.54 per share
• Price / Book: 1.39

Miscellaneous

• Outstanding Shares: 1,701,950,000
• Free Float: N/A
• Market Cap: $15.42 billion
• Optionable: Not Optionable
• Beta: 0.08